Cargando…
GSK983: A novel compound with broad-spectrum antiviral activity
GSK983, a novel tetrahydrocarbazole, inhibits the replication of a variety of unrelated viruses in vitro with EC(50) values of 5–20 nM. Both replication of the adenovirus Ad-5 and the polyoma virus SV-40, and episomal maintenance of human papillomaviruses (HPV) and Epstein-Barr virus (EBV) are susce...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114156/ https://www.ncbi.nlm.nih.gov/pubmed/19187793 http://dx.doi.org/10.1016/j.antiviral.2008.12.015 |
_version_ | 1783513825563115520 |
---|---|
author | Harvey, Robert Brown, Kevin Zhang, Qin Gartland, Margaret Walton, Leslie Talarico, Christine Lawrence, Wendell Selleseth, Dean Coffield, Neil Leary, Jeffry Moniri, Kelly Singer, Sara Strum, Jay Gudmundsson, Kristjan Biron, Karen Romines, Karen R. Sethna, Phiroze |
author_facet | Harvey, Robert Brown, Kevin Zhang, Qin Gartland, Margaret Walton, Leslie Talarico, Christine Lawrence, Wendell Selleseth, Dean Coffield, Neil Leary, Jeffry Moniri, Kelly Singer, Sara Strum, Jay Gudmundsson, Kristjan Biron, Karen Romines, Karen R. Sethna, Phiroze |
author_sort | Harvey, Robert |
collection | PubMed |
description | GSK983, a novel tetrahydrocarbazole, inhibits the replication of a variety of unrelated viruses in vitro with EC(50) values of 5–20 nM. Both replication of the adenovirus Ad-5 and the polyoma virus SV-40, and episomal maintenance of human papillomaviruses (HPV) and Epstein-Barr virus (EBV) are susceptible to GSK983. The compound does not inhibit all viruses; herpes simplex virus (HSV-1), human immunodeficiency virus (HIV), and lytic replication of EBV were not susceptible at concentrations below 1 μM. GSK983 does inhibit the growth of cell lines immortalized by HTLV-1, EBV, HPV, SV40 and Ad-5, with EC(50) values in the range of 10–40 nM. Depending on the cell line, the compound induces either apoptosis or cytostasis at concentrations over 20 nM. GSK983 also inhibits cell lines immortalized by non-viral mechanisms, but has little effect on primary cells. The CC(50) values for keratinocytes, fibroblasts, lymphocytes, endothelial, and bone marrow progenitor cells are all above 10 μM. The pattern of inhibition, which includes diverse viruses as well as growth of immortalized cells of varied origins, suggests the target is a host cell protein, rather than a viral protein. Preliminary mechanism studies indicate that GSK983 acts by inducing a subset of interferon-stimulated genes. |
format | Online Article Text |
id | pubmed-7114156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71141562020-04-02 GSK983: A novel compound with broad-spectrum antiviral activity Harvey, Robert Brown, Kevin Zhang, Qin Gartland, Margaret Walton, Leslie Talarico, Christine Lawrence, Wendell Selleseth, Dean Coffield, Neil Leary, Jeffry Moniri, Kelly Singer, Sara Strum, Jay Gudmundsson, Kristjan Biron, Karen Romines, Karen R. Sethna, Phiroze Antiviral Res Article GSK983, a novel tetrahydrocarbazole, inhibits the replication of a variety of unrelated viruses in vitro with EC(50) values of 5–20 nM. Both replication of the adenovirus Ad-5 and the polyoma virus SV-40, and episomal maintenance of human papillomaviruses (HPV) and Epstein-Barr virus (EBV) are susceptible to GSK983. The compound does not inhibit all viruses; herpes simplex virus (HSV-1), human immunodeficiency virus (HIV), and lytic replication of EBV were not susceptible at concentrations below 1 μM. GSK983 does inhibit the growth of cell lines immortalized by HTLV-1, EBV, HPV, SV40 and Ad-5, with EC(50) values in the range of 10–40 nM. Depending on the cell line, the compound induces either apoptosis or cytostasis at concentrations over 20 nM. GSK983 also inhibits cell lines immortalized by non-viral mechanisms, but has little effect on primary cells. The CC(50) values for keratinocytes, fibroblasts, lymphocytes, endothelial, and bone marrow progenitor cells are all above 10 μM. The pattern of inhibition, which includes diverse viruses as well as growth of immortalized cells of varied origins, suggests the target is a host cell protein, rather than a viral protein. Preliminary mechanism studies indicate that GSK983 acts by inducing a subset of interferon-stimulated genes. Elsevier B.V. 2009-04 2009-01-31 /pmc/articles/PMC7114156/ /pubmed/19187793 http://dx.doi.org/10.1016/j.antiviral.2008.12.015 Text en Copyright © 2009 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Harvey, Robert Brown, Kevin Zhang, Qin Gartland, Margaret Walton, Leslie Talarico, Christine Lawrence, Wendell Selleseth, Dean Coffield, Neil Leary, Jeffry Moniri, Kelly Singer, Sara Strum, Jay Gudmundsson, Kristjan Biron, Karen Romines, Karen R. Sethna, Phiroze GSK983: A novel compound with broad-spectrum antiviral activity |
title | GSK983: A novel compound with broad-spectrum antiviral activity |
title_full | GSK983: A novel compound with broad-spectrum antiviral activity |
title_fullStr | GSK983: A novel compound with broad-spectrum antiviral activity |
title_full_unstemmed | GSK983: A novel compound with broad-spectrum antiviral activity |
title_short | GSK983: A novel compound with broad-spectrum antiviral activity |
title_sort | gsk983: a novel compound with broad-spectrum antiviral activity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114156/ https://www.ncbi.nlm.nih.gov/pubmed/19187793 http://dx.doi.org/10.1016/j.antiviral.2008.12.015 |
work_keys_str_mv | AT harveyrobert gsk983anovelcompoundwithbroadspectrumantiviralactivity AT brownkevin gsk983anovelcompoundwithbroadspectrumantiviralactivity AT zhangqin gsk983anovelcompoundwithbroadspectrumantiviralactivity AT gartlandmargaret gsk983anovelcompoundwithbroadspectrumantiviralactivity AT waltonleslie gsk983anovelcompoundwithbroadspectrumantiviralactivity AT talaricochristine gsk983anovelcompoundwithbroadspectrumantiviralactivity AT lawrencewendell gsk983anovelcompoundwithbroadspectrumantiviralactivity AT sellesethdean gsk983anovelcompoundwithbroadspectrumantiviralactivity AT coffieldneil gsk983anovelcompoundwithbroadspectrumantiviralactivity AT learyjeffry gsk983anovelcompoundwithbroadspectrumantiviralactivity AT monirikelly gsk983anovelcompoundwithbroadspectrumantiviralactivity AT singersara gsk983anovelcompoundwithbroadspectrumantiviralactivity AT strumjay gsk983anovelcompoundwithbroadspectrumantiviralactivity AT gudmundssonkristjan gsk983anovelcompoundwithbroadspectrumantiviralactivity AT bironkaren gsk983anovelcompoundwithbroadspectrumantiviralactivity AT romineskarenr gsk983anovelcompoundwithbroadspectrumantiviralactivity AT sethnaphiroze gsk983anovelcompoundwithbroadspectrumantiviralactivity |